Holocene Advisors LP Sells 54,194 Shares of Edwards Lifesciences Co. (NYSE:EW)

Holocene Advisors LP lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 1.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,807,467 shares of the medical research company’s stock after selling 54,194 shares during the quarter. Holocene Advisors LP’s holdings in Edwards Lifesciences were worth $185,265,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Centiva Capital LP acquired a new stake in Edwards Lifesciences during the third quarter worth $295,000. Cinctive Capital Management LP bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $3,693,000. Benjamin Edwards Inc. boosted its position in shares of Edwards Lifesciences by 6,929.4% during the 3rd quarter. Benjamin Edwards Inc. now owns 15,324 shares of the medical research company’s stock valued at $1,011,000 after acquiring an additional 15,106 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in Edwards Lifesciences in the third quarter valued at about $66,000. Finally, FSA Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter worth about $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EW. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Oppenheimer reissued an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Thursday, September 12th. Canaccord Genuity Group reduced their target price on shares of Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, October 25th. Finally, Evercore ISI dropped their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $76.85.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 in the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $71.45 on Monday. The company has a market cap of $42.14 billion, a PE ratio of 10.30, a PEG ratio of 4.01 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company’s 50-day moving average is $68.10 and its two-hundred day moving average is $75.05.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business posted $0.59 earnings per share. Edwards Lifesciences’s revenue was up 8.9% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.